TABLE 5.

Cox proportional hazards models for prognosis in non-diabetic patients.

	Univariate		Multivariate
	HR (95% CI)	P-value	HR (95% CI)	P-value
MACE
Big ET-1*	0.84 (0.55–1.28)	0.415	0.82 (0.50–1.33)	0.418
Big ET-1 tertile 1	Reference	–	Reference	–
Big ET-1 tertile 2	1.42 (0.87–2.32)	0.16	1.62 (0.90–2.90)	0.107
Big ET-1 tertile 3	0.85 (0.47–1.53)	0.581	0.85 (0.40–1.81)	0.668
Secondary endpoints
Big ET-1*	0.74 (0.49–1.13)	0.162	0.82 (0.50–1.33)	0.417
Big ET-1 tertile 1	Reference	–	Reference	–
Big ET-1 tertile 2	1.31 (0.81–2.11)	0.266	1.45 (0.83–2.53)	0.191
Big ET-1 tertile 3	0.67 (0.37–1.23)	0.195	0.76 (0.36–1.61)	0.474

*Big endothelin-1 (ET-1) was natural log-transformed. Major adverse cardiovascular events (MACE) model adjusted for age, sex, left ventricular ejection fraction (LVEF), in-stent restenosis (ISR) duration, hypertension, drug-eluting stent (DES) intervention, total cholesterol (TC), and diameter stenosis rate. Secondary end points model adjusted for age, sex, high-density lipoprotein cholesterol (HDL-c), TC, reference vessel diameter, target lesion length, and diameter stenosis rate.